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Objectives: This study evaluated the virological efficacy of dolutegravir 50 mg twice daily in 190 HIV-1 failing
antiretroviral-experienced patients with previous exposure to first-generation integrase strand transfer inhibitor
(INSTI) over a 5 year follow-up using data from clinical practice.
Patients and methods: This analysis included HIV-1-infected patients who were 18 years of age, treatment
experienced, had HIV-1 RNA.50 copies/mL, with INSTI-resistant virus, who started dolutegravir 50 mg twice daily
plus optimized background therapy (OBT), recorded in the national prospective database PRESTIGIO (www.proget
toprestigio.it). Follow-up accrued from the start of dolutegravir 50 mg twice daily!OBT until virological failure (VF)
or dolutegravir discontinuation for any reason or the last treatment visit on dolutegravir 50 mg twice daily treat-
ment. VF was defined by the lack of achievement of HIV-1 RNA,50 copies/mL by 6 months and thereafter, or the
occurrence of two consecutive HIV-1 RNA50 copies/mL after achievement of undetectable viral load.
Results: The estimated VF probabilities were 17% (95% CI"12%–24%), 28% (95% CI"21%–37%), 33% (95%
CI"25%–43%), 39% (95% CI"29%–51%) and 52% (95% CI"39%–67%) at 12, 24, 36, 48 and 60 months
since baseline, respectively. A higher risk of VF was independently associated with baseline viral load
.100000 copies/mL (adjusted HR"4.73, 95% CI"1.33–16.78, P"0.016) and with 1 INSTI mutations plus
Q148H/K/R/N and the G140S/A/C as compared with other subjects (adjusted HR"4.18, 95% CI" 1.32–13.23,
P"0.015).
Conclusions: Our data showed a favourable long-term efficacy of dolutegravir 50 mg twice daily in association
with OBT in treatment-experienced failing subjects, with INSTI-resistant virus, in the real world. A close monitor-
ing of adherence is crucial for maintenance of virological response in this fragile subgroup of subjects.
Introduction
The availability of an effective rescue therapy for HIV-1-infected
subjects with previous failure to an integrase strand transfer inhibi-
tor (INSTI)-based regimen is an emerging clinical issue.
Resistance to INSTIs in antiretroviral-experienced patients has
emerged in recent years,1,2 with heterogeneous prevalence rates,
ranging from 15.6% among treated subjects with an available INSTI
resistance test in the USA between 2009 and 20123 to 3.4% in
French treated subjects experiencing virological failure (VF) in 2014.4
Dolutegravir 50 mg twice daily with an optimized background
therapy (OBT) has been proven to be effective as rescue therapy in
treatment-experienced patients harbouring an INSTI-resistant
virus,5–7 with virological response rates ranging from 47%7 to
75%5 at week 24 and 40% at week 48;7 no data are available for
longer follow-up.
This study aimed to evaluate the long-term efficacy of dolute-
gravir 50 mg twice daily in combination with OBT, assessed by time
to VF, among treatment-experienced HIV-1-infected failing sub-
jects with INSTI-resistant virus using data from clinical practice.
VC The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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Patients and methods
HIV-1-infected patients who were 18 years of age, treatment experienced,
had HIV-1 RNA .50 copies/mL, had INSTI-resistant virus [at baseline (BL) or
previously documented], who started dolutegravir 50 mg twice daily plus OBT
were included in this study. Patients’ information is prospectively recorded in
the national electronic database PRESTIGIO, implemented in November 2014,
based on a request of the Italian Medicines Agency (AIFA, Agenzia Italiana del
Farmaco) aimed at monitoring the appropriateness of dolutegravir 50 mg
twice daily prescriptions (www.progettoprestigio.it). The database includes
patients on treatment with dolutegravir 50 mg twice daily at the time of the
drug marketing authorization in Italy or those who started this drug thereafter
and records, at least annually, demographic (age, gender, ethnicity), clinical
(HCV coinfection, date of first HIV-positive test, prescribed antiretroviral drugs,
reasons for discontinuation, death) and virological [viral load (VL), drug-
resistance tests] and immunological (CD4! cell count) characteristics.
Ethics Committees of 40 Italian Infectious Diseases Clinical Centres
were notified of the PRESTIGIO data collection, required by AIFA; owing to
this mandatory request, informed consent was not covered.
Follow-up accrued from the date of dolutegravir 50 mg twice daily plus
OBT start (BL) until the date of VF or dolutegravir discontinuation for any
reason or participation to randomized clinical trials on experimental drugs
or the last treatment visit on dolutegravir 50 mg twice daily treatment (last
update 31 January 2017), whichever occurred first.
The genotypic susceptibility score (GSS) was determined both for the BL
dolutegravir 50 mg twice daily-based regimen (i.e. dolutegravir plus OBT;
total GSS) and for OBT only (GSSOBT) of each study participant by use of the
Stanford University HIV Drug Resistance Database (version 8.3, last updated
2 March 2017):8 for each drug, ‘susceptible’ or ‘potential low-level or low-
level resistance’ was scored as 1 point and ‘intermediate or high-level resist-
ance’ was scored as 0 points. The total GSS and the GSSOBT were calculated
as the sum of the scores for the individual drugs included in the BL regimen.
Table 1. Patients’ characteristics at the start of dolutegravir 50 mg twice
daily plus OBT (BL)
Characteristic
Median (IQR) or
frequency (%),
(n"190)
Age (years) 50.6 (45.4–54.0)
Male gender 138 (73%)
Italian nationality 174 (92%)
HCV coinfection 61 (32%)
Years since HIV-1 infection 21.0 (15.0–25.0)
Previous inclusion in the VIKING or EAP 59 (31%)
BL DTG calendar year
2014 69 (36%)
2015 86 (45%)
2016 35 (18%)
BL HIV-1 RNA (log10 copies/mL) 3.69 (2.72–4.64)
.100000 copies/mL 36 (19%)
BL CD4! (cells/mm3) 299 (138–518)
200 cells/mm3 68 (36%)
OBT
OBT .3 drugs (including DTG) 49 (26%)
PI-sparing regimens 48 (25%)
NNRTI-sparing regimens 136 (72%)
NRTI-sparing regimens 106 (56%)
NRTI most frequently used
TDF 52 (27%)
FTC 42 (22%)
3TC 30 (16%)
NNRTI most frequently used
ETV 39 (21%)
RPV 12 (6%)
PI/r most frequently used
DRV/r 117 (62%)
ATV/r 13 (7%)
LPV/r 9 (5%)
enfuvirtide use 11 (6%)
maraviroc use 41 (22%)
HIV-1 co-receptor tropism
false positive rate (FPR; available in 107 subjects) 15.8 (2.3–48.8)
non-R5 (FPR ,10%) 54/117 (46%)
R5 (FPR10%) 63/117 (54%)
Genotypic drug-resistance test
HIV-1 subtype strains (available in 95 subjects)
B 87 (91.7%)
CRF02 AG 2 (2.1%)
D/B 2 (2.1%)
F 2 (2.1%)
C 1 (1.0%)
CRF28 BF 1 (1.0%)
1 PI resistance mutation 77/142 (54%)
1 NNRTI resistance mutation 80/142 (56%)
1 NRTI resistance mutation 96/142 (68%)
1 INSTI resistance mutation 117/142 (82%)
2 INSTI resistance mutations 77/142 (54%)
1 major primary INSTI resistance mutation 105/142 (74%)
Continued
Table 1. Continued
Characteristic
Median (IQR) or
frequency (%),
(n"190)
Q148H/K/R/N 45 (32%)
N155H 44 (31%)
G140S/A/C 36 (25%)
Y143C/R/H 15 (11%)
E138K/A/T 13 (9.2%)
T66A/I/K 4 (2.8%)
E92Q 4 (2.8%)
S147G 4 (2.8%)
1 major accessory INSTI resistance mutation 45/142 (32%)
T97A 23 (16%)
total GSS 106/142 (75%)
0 4 (3.8%)
1 23 (22%)
2 79 (75%)
GSSOBT 106/142 (75%)
0 17 (16%)
1 46 (43%)
2 43 (41%)
3TC, lamivudine; ATV, atazanavir; DRV, darunavir; DTG, dolutegravir
50 mg twice daily; EAP, expanded access program; ETV, etravirine; FTC,
emtricitabine; LPV, lopinavir; OBT, optimized background therapy; PI, pro-
tease inhibitor; /r, combined with ritonavir; RPV, rilpivirine; TDF, tenofovir.
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HIV-1 CCR5-tropic virus was defined by a geno2pheno false positive rate
10%.
VF was defined by (i) the lack of achievement of undetectable VL (HIV-1
RNA,50 copies/mL) by 6 months and thereafter, or (ii) the occurrence of two
consecutive HIV-1 RNA50 copies/mL after achievement of undetectable VL.
Treatment failure (TF) was defined by the occurrence of VF or discontin-
uation of dolutegravir 50 mg twice daily during follow-up.
Results were described as median (IQR) or proportions. Kaplan–Meier
analysis was used to estimate and compare the time to VF (primary out-
come) and TF; time to VF was also estimated according to BL VL, BL CD4!,
BL INSTI mutations, BL total GSS and GSSOBT and curves were compared by
use of the log-rank test.
A multivariate Cox regression model was used to determine the risk factors
for VF; the model was fitted for time to VF and the effect estimate was reported
as the adjusted HR (AHR) with the corresponding 95% CI. The multivariate
model was built according to previous findings5–7,9 and included main demo-
graphic (age, gender) and clinical variables (years of HIV infection, HCV coinfec-
tion) in addition to BL CD4! cell count (200 versus .200 cells/mm3), BL VL
(100000 versus.100000 copies/mL), GSSOBT (,2 or2) and BL INSTI muta-
tions (1 mutation plus the Q148H/K/R/N and the G140S/A/C versus other).
CD4! changes from BL by timepoints (12, 24, 36, 48 and 60 months)
were also calculated.
For all analyses, two-sided P,0.05 was considered statistically signifi-
cant. All analyses were performed using the SAS Software, release 9.4
(SAS Institute, Cary, NC, USA).
Results
A total of 190 HIV-1-infected patients were analysed. Of the total,
135 (73%) were males, 174 (92%) Italian, with a median (IQR) age
of 51 (45–54) years, infected with HIV since 21 (15–25) years, 92%
infected with subtype B strains, 61 (32%) HCV coinfected. At BL,
HIV-1 RNA was 3.69 (2.72–4.64) log10 copies/mL and CD4! cell
count was 299 (138–518) cells/mm3. Dolutegravir 50 mg twice
daily was associated with3 other antiretroviral drugs in 49 (26%)
patients and darunavir/ritonavir [117 (62%)], etravirine [39 (21%)]
and tenofovir [52 (27%)] were the most frequently combined
drugs; maraviroc and enfuvirtide were used in 41 (22%) and
11 (6%) patients, respectively. At BL, 54% of patients harboured
CCR5-tropic virus. A BL INSTI resistance test was available for 142
(75%) patients: 25 (18%), 40 (28%) and 77 (54%) had 0, 1 and2
INSTI mutations, respectively; 105 (74%) had 1 primary INSTI
mutation; the Q148H/K/R/N mutation was present in 45 (32%)
patients, G140A/C/S in 36 (25%), N155H in 44 (31%) and E138A/K/
T in 13 (9%) patients; and 16% of subjects had a GSSOBT of 0. Other
patients’ characteristics are shown in Table 1.
During a median (IQR) follow-up of 17.9 (10.2–33.8) months
[median number of VL determinations per patient: 5 (4–11)], 48
(25%) VF occurred. BL and follow-up genotypic drug resistance
tests were available in 16 subjects with VF; patients’ characteristics
are detailed in Table 2.
Kaplan–Meier analysis showed that the estimated probabil-
ities of VF were 17% (95% CI"12%–24%), 28% (95%
CI"21%–37%), 33% (95% CI"25%–43%), 39% (95%
CI"29%–51%) and 52% (95% CI"39%–67%) at 12, 24, 36,
48 and 60 months since BL, respectively (Figure 1a). Time to VF
was shorter in subjects with BL CD4!200 cells/mm3 (log-rank
test, P"0.035; Figure 1c) or VL .100000 copies/mL (log-rank
test, P"0.005; Figure 1d).
Time to VF did not differ between patients with a total GSS or
GSSOBT ,2 or 2 (log-rank test: P"0.435 and P"0.699,Ta
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respectively; Figure 2a and b). Patients with GSSOBT"0 tended to
have higher VF probabilities than others (log-rank test, P"0.304;
Figure 2c); VF occurred in 7 of 17 (41%) patients with GSSOBT"0 as
compared with 17% and 21% of those with GSSOBT"1 or 2,
respectively. Time to VF was shorter also in subjects with1 INSTI
mutation in addition to the Q148H/K/R/N and the G140S/A/C
mutations (log-rank test, P"0.020; Figure 2d).
Dolutegravir 50 mg twice daily was discontinued in 28 (15%)
subjects [10 VF, 9 regimen simplification, 3 patient’s decision, 1
lost to follow-up, 1 drug-related adverse event (diarrhoea and
rash), 4 deaths (1 acute myocardial infarction, 1 suicide, 2
sepsis)].
The Kaplan–Meier analysis estimated that the TF
probabilities were 22% (95% CI"17%–29%), 36% (95%
CI"28%–45%), 41% (95% CI"33%–51%), 47% (95%
CI"37%–58%) and 58% (95% CI"46%–71%) at 12, 24, 36, 48
and 60 months since BL, respectively (Figure 1b).
The median change in CD4! cell count since BL was !65 (#6,
!181), !130 (!12, !249), !203 (!107, !295), !269 (!119,
!399) and !279 (!118, !427) cells/mm3 at 12, 24, 36, 48 and
60 months, respectively.
After adjusting for age, gender, years of HIV infection, HCV coin-
fection, BL CD4! cell count and GSSOBT, a higher risk of VF was
found for patients with BL VL .100000 copies/mL (AHR"4.73,
95% CI"1.33–16.78, P"0.016) and with1 INSTI mutation plus
Q148H/K/R/N and the G140S/A/C as compared with other subjects
(AHR"4.18, 95% CI"1.32–13.23, P"0.015).
Discussion
Overall, we found that 75% of the patients achieved undetectable
VL and that 48% of subjects had a durable virological suppression
up to 5 years after starting dolutegravir 50 mg twice daily.
Our results confirm the high long-term efficacy of dolutegravir
50 mg twice daily when added to an OBT in treatment-
experienced subjects with INSTI-resistant virus and, in some cases,
with very limited treatment options. The high response rates
observed in this study likely reflect the real practice in which dolu-
tegravir 50 mg twice daily was started in subjects previously
treated with antiretroviral regimens including first-generation
INSTI drugs and those with a higher CD4! cell count, lower VL,
lower number of INSTI resistance mutations at BL and more
remaining therapeutic options than those enrolled in the VIKING
studies.5–7 As expected, also in our study, subjects with GSSOBT"0
tended to have the lower proportions of virological response.
Virological efficacy was affected by BL VL and the type and
number of INSTI mutations, consistent with what has been
reported in other previous studies.6,10
The main limitations of this study include the lack of collection
of adherence data, known to be one of the stronger factors
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Figure 1. Estimated probabilities of VF and TF in the overall sample (a and b, respectively). Estimated probabilities of VF according to BL CD4! (c) and
BL VL (d). DTG, dolutegravir 50 mg twice daily.
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associated with either VF or emergence of INSTI resistance;11 the
lack of adherence may partially explain both the high BL VL and
the absence of INSTI resistance at failure observed in some cases.
In addition, our results may not apply to subjects with different
ethnicity and HIV-1 subtype.
In subjects with an extensive degree of INSTI resistance at BL a
limited further genotype evolution has been observed at VF,
although this observation is preliminary, owing to the very limited
sample size of subjects with available data. A potential explanation
is that most of these subjects had the Q148/G140 INSTI mutations,
which are known to cause up to a 10–20-fold reduced susceptibil-
ity to dolutegravir particularly when a third INSTI resistance muta-
tion is also present.1 A clearer interpretation of INSTI resistance
evolution in subjects with VF could be also achieved by measuring
cumulative rather than circulating resistance.
It is interesting to note that initiation of dolutegravir 50 mg
twice daily and VF occurred in patients with highly heterogeneous
CD4 values; moreover, dolutegravir 50 mg twice daily was main-
tained in 79% of subjects with VF, likely due to a lack of therapeutic
alternatives. These findings outline the need for new drugs and
new strategies12–14 for the immediate and long-term manage-
ment of subjects with different risks of disease progression.
In conclusion, our data showed a favourable long-term efficacy
of dolutegravir 50 mg twice daily in association with OBT in
treatment-experienced failing subjects, with INSTI-resistant virus, in
the real world. Close monitoring of adherence is crucial for mainte-
nance of the virological response in this fragile subgroup of subjects.
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